Immunotech Biopharm (HKSE:06978) EBIT per Share : HK$-0.64 (TTM As of Jun. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Immunotech Biopharm EBIT per Share?

Immunotech Biopharm's EBIT per Share for the six months ended in Jun. 2024 was HK$-0.19. Its EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2024 was HK$-0.64.

During the past 3 years, the average EBIT per Share Growth Rate was 22.50% per year. During the past 5 years, the average EBIT per Share Growth Rate was -34.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Immunotech Biopharm's EBIT per Share or its related term are showing as below:

HKSE:06978' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -102.7 Med: -33.1 Max: 22.5
Current: 22.5

During the past 6 years, the highest 3-Year average EBIT per Share Growth Rate of Immunotech Biopharm was 22.50% per year. The lowest was -102.70% per year. And the median was -33.10% per year.

HKSE:06978's 3-Year EBIT Growth Rate is ranked better than
71.79% of 1223 companies
in the Biotechnology industry
Industry Median: 4.7 vs HKSE:06978: 22.50

Immunotech Biopharm's EBIT for the six months ended in Jun. 2024 was HK$-95.50 Mil.

Immunotech Biopharm EBIT per Share Historical Data

The historical data trend for Immunotech Biopharm's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunotech Biopharm EBIT per Share Chart

Immunotech Biopharm Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

-0.24

-1.17

-0.84

-0.68

-0.70

Immunotech Biopharm Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
EBIT per Share	Get a 7-Day Free Trial							-0.32	-0.38	-0.24	-0.45	-0.19

Immunotech Biopharm EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Immunotech Biopharm's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-357.622	/	514.584
=	-0.69

Immunotech Biopharm's EBIT per Share for the quarter that ended in Jun. 2024 is calculated as

	EBIT per Share		(Q: Jun. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-95.495	/	514.584
=	-0.19

EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-0.64

Immunotech Biopharm (HKSE:06978) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Immunotech Biopharm EBIT per Share Related Terms

Thank you for viewing the detailed overview of Immunotech Biopharm's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Immunotech Biopharm Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunotech Biopharm Ltd (HKSE:06978) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

No.1 Kangding Street, 8th Floor, Block 1, Guosheng Technology Park, Beijing Economic-technological Development Area, Beijing, CHN, 100176

Website

https://www.eaal.net

Immunotech Biopharm Ltd is a cellular immunotherapy biopharmaceutical company in China. The company is focused on the research, development, and commercialization of T-cell immunotherapy. Its product EAL is a multi-target cellular immunotherapy product for the treatment of various types of cancer. Its product pipeline features classes of cellular immunotherapy products, including both non-genetically modified and genetically modified products, as well as both multi-target and single-target products. Its other products include the CAR-T cell series and the TCR-T cell series.

Executives

Jung Hyun Chul
Evodevo Ltd
Yan Kaijing	2501 Other
Xi Zang Jia Ze Chuang Ye Tou Zi You Xian Gong Si	2101 Beneficial owner
Jiang Su Ji Chuan Kong Gu Ji Tuan You Xian Gong Si	2201 Interest of corporation controlled by you
Cao Longxiang	2201 Interest of corporation controlled by you
Cao Fei	2201 Interest of corporation controlled by you
Tian Jin Fu Hua De Ke Ji Kai Fa You Xian Gong Si	2501 Other
Yan Xijun	2501 Other
Wu Naifeng	2501 Other
Tasly (hong Kong) Pharmaceutical Investment Limited	2501 Other
Li Yunhui	2501 Other
Hua Run San Jiu Yi Yao Gu Fen You Xian Gong Si	2201 Interest of corporation controlled by you
China Resources Pharmaceutical Group Limited	2201 Interest of corporation controlled by you
China Resources Company Limited	2201 Interest of corporation controlled by you

Immunotech Biopharm Headlines

No Headlines